US government agency to investigate FDA over rofecoxibBMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7472.935 (Published 21 October 2004) Cite this as: BMJ 2004;329:935
- Jeanne Lenzer
- New York
The US Government Accountability Office, a regulatory watch-dog on federal government spending, is to investigate claims that the Food and Drug Administration attempted to silence one of its senior medical officers when he tried to warn that rofecoxib (Vioxx) caused heart attacks and strokes.
The drug was withdrawn on 30 September by its manufacturers, Merck, after a study found a fourfold increase in serious thromboembolic adverse events in patients receiving rofecoxib compared with patients receiving placebo (BMJ 2004;329: 816, 9 Oct).
David Graham, associate director for science in the FDA Drug Center's Office of Drug Safety, said that he was subjected to “veiled threats” …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial